Early detection of liver cancer is crucial for the effective treatment of the disease. Surgical treatment of early-stage liver cancer can achieve up to 90% long term survival. In contrast, late-stage liver cancer has a median survival of less than a year when not eligible for surgery. Unfortunately, many early-stage liver cancer cases have mild symptoms and miss the opportunity for early detection. Our HCC Fusion Predictor, a serum fusion gene test, has up to 95% accuracy and detects liver cancer even when other serum markers, such as α-fetal protein, are within the normal range. Since the doubling time for HCC is only 4-5 months, high-risk individuals should have this screening test performed annually or semi-annually.